白蛋白结合 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
One of the basic tenets of TCM is that the body's qi (sometimes translated as vital energy) is circulating through channels called meridians having branches connected to bodily organs and functions. The concept of vital energy is pseudoscientific. Concepts of the body and of disease used in TCM reflect its ancient origins and its emphasis on dynamic processes over material structure, similar to Classical humoral theory. TCM has also been controversial within China. In 2006, the Chinese philosopher Zhang Gongyao triggered a national debate with an article entitled "Farewell to Traditional Chinese Medicine", arguing that TCM was a pseudoscience that should be abolished in public healthcare and academia. The Chinese government took the stance that TCM is a science and continued to encourage its development. There are concerns about a number of potentially toxic plants, animal parts, and mineral compounds from China, as well as the facilitation of disease. Trafficked and farm-raised animals used in TCM are a source of several fatal zoonotic diseases. There are additional concerns over the illegal trade and transport of endangered species including rhinoceroses and tigers, and the welfare of specially farmed animals, including bears. Many TCM remedies are effective because they are combined with modern Western medicine. An example is the popular over-the-counter cold medication Ganmaoling Keli (Chinese: 感冒灵颗粒; pinyin: Gǎnmàolíng Kēlì; lit.
== USDA 1923-1942 == By now Lore Rogers had served the USDA for nearly two decades as Chief of the Research Laboratories. In 1923 the University of Maryland awarded him an honorary D. Sc. degree. He was now Dr. Rogers. Two years later his alma mater, the University of Maine, also conferred the D. Sc. degree to him. He was serving as president of the Society of American Bacteriologists and as associate editor of the Journal of Bacteriology. The World Dairy Congress was to be held in Washington in 1923, and Rogers volunteered to head the program committee. In 1928 he was off to London as a delegate to the 10th International Dairy Congress. A most remarkable book was published in 1928. Fundamentals of Dairy Science had about 31 contributing authors. The title page, however, merely states
For light microscopy, paraffin wax is the most frequently used embedding material. Paraffin is immiscible with water, the main constituent of biological tissue, so it must first be removed in a series of dehydration steps. Samples are transferred through a series of progressively more concentrated ethanol baths, up to 100% ethanol to remove remaining traces of water. Dehydration is followed by a clearing agent (typically xylene although other environmental safe substitutes are in use) which removes the alcohol and is miscible with the wax, finally melted paraffin wax is added to replace the xylene and infiltrate the tissue. In most histology, or histopathology laboratories the dehydration, clearing, and wax infiltration are carried out in tissue processors which automate this process. Once infiltrated in paraffin, tissues are oriented in molds which are filled with wax; once positioned, the wax is cooled, solidifying the block and tissue.
== Bibliography == Greenwood, Norman N.; Earnshaw, Alan (1997). Chemistry of the Elements (2nd ed.). Butterworth–Heinemann. ISBN 978-0080379418. Haire, Richard G. (2006). "Einsteinium". In Morss, Lester R.; Edelstein, Norman M.; Fuger, Jean (eds.). The Chemistry of the Actinide and Transactinide Elements (PDF). Vol. 3 (3rd ed.). Dordrecht, the Netherlands: Springer. pp. 1577–1620. doi:10.1007/1-4020-3598-5_12. ISBN 978-1-4020-3555-5. Archived from the original (PDF) on 2010-07-17. Holleman, Arnold F. & Wiberg, Nils (2007). Textbook of Inorganic Chemistry (102nd ed.). Berlin: de Gruyter. ISBN 978-3-11-017770-1. Seaborg, G.T., ed. (23 January 1978). Proceedings of the Symposium Commemorating the 25th Anniversary of Elements 99 and 100 (PDF). Report LBL-7701.
=== eRF3 binding === The binding of eRF3 and GTP to eRF1 to form a complex is essential for termination of translation. The interaction between the C domains of both eRF1 and eRF3 is the major force holding the complex together. However, it was later discovered that the M domain also contributes to the stability of the complex. The positioning of eRF3 near the GGQ motif, which is in the C domain, allows greater catalytic effects of eRF1 hydrolyzing the peptidyl-tRNA.
Sources: en.wikipedia.org
=== Micro DisplayPort === Micro DisplayPort would have targeted systems that need ultra-compact connectors, such as phones, tablets and ultra-portable notebook computers. This standard would have been physically smaller than the currently available Mini DisplayPort connectors. The standard was expected to be released by Q2 2014.
=== Plasmonic biosensors === Chilkoti introduced an optical method to quantify biomolecular interactions in real time at the surface of an optically transparent substrate. He used this approach to design a label-free plasmonic biosensor in a chip format. Furthermore, he identified several factors to improve the performance of immobilized metal nanoparticle sensors. Moreover, he also conducted a study to discuss the applications of tunable absorption in designing controlled-emissivity surfaces for thermophotovoltaic devices, producing detector elements for imaging and tailoring an infrared spectrum for controlled thermal dissipation.
A free downloadable (PC) version — latest release AIDA v4.3b — which also works on Apple Macintosh computers running PC emulation software. A web-based version — called AIDA on-line — available to use via a standard web browser.
== Etymology == The name Cossack (Russian: казак, romanized: kazak; Ukrainian: козак, romanized: kozak) was widely used to characterise "free people" (compare Turkic qazaq, which means "free men") as opposed to others with different standing in feudal society (i.e., peasants, nobles, clergy, etc.). The name "cossack" was also applied to migrants, free-booters and bandits. It has the same etymological root as "Kazakh", an unrelated Central Asian Turkic people.
=== Genetics === The sequencing of a full cephalopod genome has remained challenging to researchers due to the length and repetition of their DNA. The characteristics of cephalopod genomes were initially hypothesized to be the result of entire genome duplications. Following the full sequencing of a California two-spot octopus, the genome showed similar patterns to other marine invertebrates with significant additions to the genome assumed to be unique to cephalopods. No evidence of full genome duplication was found. Within the California two-spot octopus genome there are substantial replications of two gene families. Significantly, the expanded gene families were only previously known to exhibit replicative behaviour within vertebrates. The first gene family was identified as the protocadherins which are attributed to neuron development. Protocadherins function as cell adhesion molecules, essential for synaptic specificity. The mechanism for protocadherin gene family replication in vertebrates is attributed to complex splicing, or cutting and pasting, from a locus. Following the sequencing of the California two-spot octopus, researchers found that the protocadherin gene family in cephalopods has expanded in the genome due to tandem gene duplication. The different replication mechanisms for protocadherin genes indicate an independent evolution of protocadherin gene expansion in vertebrates and invertebrates. Analysis of individual cephalopod protocadherin genes indicate independent evolution between species of cephalopod.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.